Palivizumab for prophylaxis against respiratory syncytial virus infection in children with cystic fibrosis

Medicine & Life Sciences

• Palivizumab 100%
• Respiratory Syncytial Virus Infections 82%
• Cystic Fibrosis 62%
• Respiratory Syncytial Viruses 34%
• Child 27%
• Placebos 20%
• Hospitalization 12%
• Safety 10%
• Pseudomonas 6%
• Mortality 5%
• Inborn Genetic Diseases 5%
• Critical Care 5%
• Patient Selection 5%
• Intensive Care Units 4%
• Pneumonia 4%
• Data Analysis 4%
• Chronic Disease 4%
• Randomized Controlled Trials 3%
• Weights and Measures 3%
• Morbidity 3%
• Lung 3%
• Incidence 2%
• Infections 2%
• Therapeutics 1%